Managing Partner (based in Montreal) Dr. Birner is responsible for TVM Capital Life Sciences’ overall investment strategy going forward and the fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Evotec AG (Hamburg, Germany) and Proteon Therapeutics, Inc (Kansas City, Missouri). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. respectively.
General Partner Corporate Finance (based in Boston)
Mr. Cipriano joined TVM Capital in 2000 and serves as general partner in corporate finance at TVM Capital in Boston. He concentrates on all issues of corporate finance involving life science portfolio companies. He is responsible for structuring and coordinating the investment process from a finance, tax and legal perspective; performing financial due diligence and valuation analysis; negotiating term sheets and legal documents; monitoring investments; and providing operational support to portfolio companies.
General Partner Corporate Finance and Head of Finance (based in Munich)
Stefan Fischer joined TVM Capital in 2000 and is General Partner Corporate Finance at TVM Capital in Munich. In this role, he concentrates on all Corporate Finance issues involving life science portfolio companies. He is responsible for structuring and coordinating the investment process from a finance, tax and legal perspective; performing financial due diligence and valuation analysis; negotiating term sheets and legal documents; monitoring investments; and providing operational support to portfolio companies. He is member of the supervisory board of Direvo IBT GmbH, Cologne, and also serves as a board observer to Biovertis AG, Vienna.
General Partner (based in Munich)
Dr. Alexandra Goll, who joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. She was an initial investor in Actelion Ltd (Allschwil, Switzerland) and a Series B lead investor of Idenix Pharmaceuticals, Inc. (Cambridge, Massachusetts). Dr. Goll was a member of the Board of Directors of Idenix until the sale of 51% of the company to Novartis in May 2003.
General Partner (based in Montreal)
Dr. Lavoie assumes responsibility for the implementation of the TVM Capital investment strategy in Canada. Dr. Lavoie is joining TVM Capital after more than eight years with VG Partners, a large Canadian private equity firm, where her most recent role was as partner and Head of Life Sciences. She served on the boards of investee companies Aegera Therapeutics Inc. (Montréal, QC; sold to Pharmascience Inc.), Cytochroma Inc. (Markham, ON), Interface Biologics Inc. (Toronto, ON), Trillium Therapeutics (Toronto, ON) and Zelos Therapeutics Inc. (West Conshohocken, PA).
Managing Partner (based in Montreal)
Dr. Marengere oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution.
Dr. Marengere joins TVM Capital after more than 15 years of venture capital experience in Canada and the U.S. Most recently, Dr. Marengere was a Managing General Partner with VG Partners where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF).
Venture Partner (based in Munich)
Dr. Peter Neubeck is currently a Chief Business Officer at Aspireo Pharmaceuticals Ltd. As a venture partner at TM Capital, he supports deal origination and the evaluation of new investments, as well as research and support for existing portfolio companies with an emphasis on clinical development stage to commercial stage investments, including virtual asset development type investments (‘Project-Focused-Companies’).
General Partner (based in Munich)
Dr. Axel Polack joined TVM Capital in 2000. As an investment manager he makes investments for the Fund in Project-Focused Companies as well as traditional venture capital investments. Dr. Polack’s main scientific fields of expertise are molecular and viral oncology, oncogene activation, gene regulation and molecular immunology. He works intensively on the assessment of new investment opportunities in those areas, while also providing support to existing portfolio companies.
Chairman & Managing Partner (based in Munich and Dubai)
Since joining TVM Capital in 1990, Dr. Schühsler has been the deal maker on more than 20 direct investments in life science companies in Europe and the U.S. In total he has overseen more than 80 investments in the health market and has built the TVM Life Science practice as an internal start up within the firm to its market position today.